StockData

Alumis vs HCW Biologics

ALMS and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALMS and HCWB compare

Alumis is the larger company, worth 439 times as much as HCW Biologics ($626M against $1.4M).

HCW Biologics keeps more of each dollar of sales as profit, with a net margin of −83.8% compared with −5933% at Alumis.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALMSHCWB
Size and price
Market cap$626M$1.4M
Share price$4.84$0.777
Change, 1 year−12.3%−95.7%
Change, 5 years–−99.9%
Beta (5Y)2.172.48
Employees224–
StockData Score
Total score66
Valuation score13 (better)
Growth score02 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S84.7×0.2× (better)
P/B1.4×0.2× (better)
FCF yield−56.2%–
Fair value–$15.10
Margin of safety–94.9%
Growth
Revenue growth (TTM)–700%
Revenue growth, 5Y average–−57.9%
Profitability
Gross margin–96.7%
Operating margin−6204%−115% (better)
Net margin−5933%−83.8% (better)
FCF margin−4755%–
Return on equity−93.6% (better)−151%
Return on invested capital–−70.7%
Financial health
Debt / equity0.000.88 (better)
Interest coverage–−14.0×
Current ratio6.74 (better)0.06
Altman Z-score−1.13 (better)−7.21
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions91.3%5.6%
Held by insiders30.5%34.9%
Insider net buying, 12 months$44.7M (better)$532K
Short interest, % of float12.3%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.